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Left ventricular diastolic dysfunction (LVDD) of the heart is a condition where the heart
does not relax properly. This condition is important during times of stress, as LVDD is
associated with significant morbidity of elderly surgical patients. LVDD is often
asymptomatic and unrecognized as many of these patients have normal ejection
fractions. However, LVDD may lead to heart failure in patients with preserved systolic
function, with the incidence being as high as 50% in hospitalized elderly patients. The
diagnosis of LVDD is an independent risk factor for postoperative major adverse cardiac
events (MACE) and negatively impacts post-surgery readmission rates.
Anesthesiologists play a critical role in the care of elderly patients by managing fluid
therapy during surgery. Current standard of care is to manage elderly patients with
LVDD using only blood pressure monitoring. Unfortunately blood pressure monitoring is
unable to detect changes in diastolic function, which fluid administration may affect. In
contrast, transesophageal echocardiography (TEE) can easily measure diastolic function
in real-time in the operating rooms. No current studies, however, have assessed
changes to diastolic function in response to fluid boluses during noncardiac surgery.
Therefore, it is important to serially evaluate LVDD intraoperatively with TEE and
determine if changes in anesthetic management, specifically the response to fluid
boluses, has effects on diastolic indices. The specific aim of this study is evaluate

changes in left ventricular filling pressures and cardiac output in response to fluid
boluses during the perioperative period. We predict echocardiographic diastolic indices
are influenced by intraoperative fluid administration.
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CHAPTER 1: INTRODUCTION
Left ventricular diastolic dysfunction (LVDD) is a common disease in the rapidly
growing elderly patient population and a major risk factor for heart failure (HF) 1,2 3,4,5 In
the United States, more Medicare dollars are spent on the diagnosis and treatment of
HF than any other diagnosis. 6 A recent study of 1000 elderly surgical patients found that
LVDD was found preoperatively in 50% of patients undergoing vascular surgery, of
which 80% were asymptomatic. 7,8 Often asymptomatic, LVDD is an independent
predictor of postoperative morbidity and mortality. 9,10,11 Echocardiography is noninvasive
and can measure diastolic function in real-time during the perioperative period. However,
randomized clinical trials describing the use of echocardiography to guide intraoperative
management have not been reported.8 Based on pilot data, we believe
echocardiography-derived diastolic indices are influenced by anesthetic management;
thus monitoring these indices and adjusting clinical algorithms accordingly can affect risk
of postoperative major adverse cardiac events (MACE).
LVDD and Anesthetic Management
The goal of anesthesiologists taking care of elderly surgical patients is to
maximize the patient’s circulatory function by optimizing cardiac output (CO) and
ventricular filling pressures. The use of electrocardiogram (ECG) monitoring and
systemic blood pressure is the standard of care for assessing circulatory function.
However, these measurements are not barometers of diastolic function. Even the most
invasive monitors, such as central venous pressure and pulmonary artery catheters
(PACs), lack the ability to evaluate diastolic function and have not been shown to improve
survival in elderly surgical patients.9,12 Because of the invasive nature of PACs and a lack
of supportive evidence, they are not used in most noncardiac surgeries. Management of
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these high-risk patients is left to noninvasive blood pressure monitoring, which can only
serve as a surrogate measurement of filling pressures and CO.
LVDD and Fluid Management
Anesthesiologists are the perioperative primary care physicians of elderly
patients undergoing more than 14 million procedures a year. They guide fluid
management, alter vascular compliance, and treat sympathetic stimulation—all of which
may impact clinical outcomes in patients with LVDD. 13 With a diagnosis of diastolic
dysfunction, a person accumulates approximately $110,000 in medical expenses over
an average of four years from diagnosis to death. The average estimated LVDD-related
hospitalization charge is $73,762 per person, with outpatient costs exceeding $25,000
per person.6 While it is known that these older patients often have LVDD and that LVDD
is an independent risk factor of mortality, it is not known how LVDD changes under
standard operating conditions or if those changes influence or predict clinical
outcomes. 14 ,15 Standard guidelines or consensus statements on how to manage
perioperative LVDD do not exist, despite billions in yearly health care expenditures.4
Current anesthesia standards of care for fluid and drug management is no different in
the elderly patient than the younger patient, even though elderly patients with LVDD
undergoing surgery may need different fluid and drug management to optimize loading
conditions.
Background
Previous investigations have shown that varying degrees of LVDD carry different
risks of mortality; therefore, the ability to detect patients who are considered “high-risk”
may lead to a change in current anesthesia practice. In a cross-sectional population study
done by Redfield and colleagues in over 2,000 people aged 45 years or older, the
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prevalence of diastolic dysfunction was over 20 percent and had an 8.31 times higher
risk of mortality. Those with moderate (6.6% prevalence) and severe LVDD (0.7%
prevalence) had 10.2 times higher mortality at 5 years compared with those with normal
diastolic function.4 Grading of LVDD is commonly based on echocardiographic schema
using transthoracic echocardiography (TTE). Guidelines from the American Society of
Echocardiography (ASE) classify diastolic dysfunction into Grades I (Impaired
Relaxation), Grade II (Pseudonormal) or Grade III (Restrictive). 16 This grading system is
often used to assess response to therapy in epidemiological studies with TTE; however,
the utility for assessment of LVDD with transesophageal echocardiography (TEE) has
recently been studied during cardiac surgery by Swaminathan and colleagues.5,15 Their
retrospective study of over 900 patients found that a simple echo algorithm increased
classification of LVDD and that worsening grades of LVDD were associated with higher
adverse events.15
Significance
Although the grading of LVDD may differ in the operating room (OR) versus a
“snapshot” on a screening TTE, studies into whether diastolic function can actually
worsen or improve during surgery in response to fluid and drug therapy have not been
completed. Although it is known that a worsening LVDD grade has a negative impact on
mortality, it is not known how often the grade of LVDD changes in the dynamic operative
room environment. Secondly, if LVDD grades are dynamic during surgery, can alterations
in fluid and drug therapy based on these changes affect outcomes? This study will
address these key questions:
How does LVDD change in response to standard anesthesia management and
surgical stimuli?
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Our ability to detect and managing LVDD in the dynamic state of the OR is
lacking. 17 Few studies have been published on the effects of anesthetic drugs on LVDD
since the early 1990s, when Pagel published his work describing the effects of inhaled
anesthetics on LVDD in animal models using invasive catheter measurements. 18, 19, 20
Anesthesiologists are the gate-keepers of two important variables that affect loading
conditions in the OR: fluids and drugs. Ongoing adjustments in fluid and drug therapy
may have significant effects on underlying LVDD.
Current anesthesia practice is to treat elderly patients with the same fluid
management strategies as younger ones. Fluids are not set on a pump, but rather “freeflowing” at the discretion of the provider. Are there optimal fluid and drug therapies that
should be targeted for elderly patients with LVDD undergoing noncardiac surgeries, as it
is known these patients are “high-risk,” even though it is “low-risk” surgery? 21 Could
noninvasive Doppler, as opposed to invasive catheter measurements, improve care?
Can echocardiography be used to guide fluid and drug management during surgery
LVDD patients?
In the perioperative setting, using echocardiography to understand how
elderly at-risk patients, with known preoperative evidence of LVDD, react to standard
anesthesia management and surgical stimuli would be highly valuable and
contribute to the limited body of knowledge on intraoperative diastolic dysfunction
and management. Recent studies in goal-directed fluid management suggest that
patients who receive fluids based on targeted left ventricular stroke volume (SV)
measurements have improved outcomes compared to patients receiving liberal or
“recipe” fluid management strategies. Several studies suggest that optimization of
fluid management can reduce perioperative cardiovascular morbidity and shorten
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hospital stay. 22,23,24 Intraoperative TEE can calculate left ventricular SV based on
adjustments in fluids or drug therapy and may help define target therapy for patients
with LVDD.
Preliminary Studies
The primary and secondary investigators completed a prospective, randomized,
IRB-approved pilot study of 28 surgical subjects identified in pre-anesthesia clinic using
TTE to have LVDD. 25 Subjects were screened on the basis of age > 65 years or
younger subjects with age-related cardiovascular phenotype. Average subject age was
69.7 years (10 male, 18 female) and average body mass index (BMI) was 30.9 kg/m2.25
Thirteen noncardiac surgeries were used for inclusion criteria, based on a previous study
done by Hammil.3 Subjects were identified to have LVDD using assessment criteria
based on guidelines from the ASE on the grading of LVDD.16 Subjects were randomized
into two groups: a Standard HEmodynamic Management group (SHEM) versus an
Echo-Guided HEmodynamic Management (EGHEM) group. Subjects in the EGHEM
group (n=14) received intraoperative TEE to manage fluids and optimize CO using left
ventricular filling patterns.
Preliminary Study Changes in LVDD
It was noted in the EGHEM group that seven of 14 subjects (50%) had no
change in LVDD grade intraoperatively while six (43%) had improvement in LVDD
grade, and one subject (7%) worsened in LVDD grade. This led us to question the
properties of diastolic indices, normally used to screen patients as a one-time
measurement in awake, spontaneously breathing patients. Our preliminary data
suggests that patients undergoing surgery may change their grade of LVDD and
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supports the hypothesis that diastolic dysfunction is dynamic in the OR. This finding lent
itself to investigate the dynamic nature of LVDD perioperatively.
Preliminary Study Changes in Fluid Management
One of the secondary aims of the preliminary study was to measure the
difference in the frequency of congestive heart failure (CHF) and atrial fibrillation (A Fib)
postoperatively between the two groups: subjects who underwent SHEM versus subjects
who underwent EGHEM. The incidence of CHF at 30 days was 21.4% in the SHEM
group and 7% in the EGHEM group.
The incidence of A Fib at 30 days
was 28.6% in the SHEM group and
14.3% in EGHEM group (Figure 1).25
One statistically significant difference
between the control and intervention
group was the amount of
intraoperative fluid administered
based on the clinical algorithm. The

Figure 1: Pilot Study. This graph demonstrates
the finding of the pilot study where clinical
outcomes at 30 days post op of CHF and A Fib
showed a trend towards decrease in the
interventional group (EGHEM) who received less
fluids when compared to the control group
(SHEM).

EGHEM group received 12.7
milliliters(mL)/kilogram(kg) of intraoperative intravenous fluid, while the SHEM group
received 33.04 mL/kg (p=0.017).25 This led to the following question: what is the exact
response of fluid to diastolic echocardiography indices and left ventricular CO? Does
fluid administration improve or worsen either measurement? This question led us to
specifically determine if goal-directed echocardiography-guided hemodynamic
management of LVDD in elderly surgical patients can change intraoperative diastolic
function.
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Perioperative Fluid Management and LVDD
It is understood that LVDD can lead to heart failure with preserved ejection
fraction, often called HFpEF. While the clinical treatment of LVDD is unclear, the
treatment of CHF, either systolic or diastolic, is aimed at decreasing afterload and
preload with the goal of lowering left-sided filling pressures and promoting forward flow
to improve organ perfusion. Optimizing fluid to minimize pulmonary congestion and
peripheral edema is an important part of the treatment and avoidance of clinical heart
failure. Utilization of diuretics is often the mainstay of therapy to prevent and or treat
CHF. Specific clinical trials looking at the treatment of diastolic heart failure have
included diuretics, beta-blockers, angiotensin converting enzyme inhibitors, drugs to
control heart rate and prevent myocardial ischemia, and drugs to promote cardiac
hypertrophy and remodeling such as phosphodiesterase-5 inhibitors and statins. The
prevention of perioperative diastolic heart failure, however, has not been addressed in
previous clinical trials. The question of what amount of intraoperative fluids should be
given to patients that have LVDD undergoing surgery has not been addressed.
In the last 10 years there has been a significant amount of literature looking at
“restrictive” fluid therapy versus “liberal” fluid therapy versus “goal directed therapy”
(GDT) in patients undergoing cardiac and noncardiac surgery. The majority of the
literature in noncardiac surgical patients has been performed in major abdominal
surgery. These studies performed in abdominal surgical cohorts have shown improved
outcomes when GDT is used.22,23,24 Little is known on the effects of GDT in patients
undergoing vascular with known diastolic function or impaired relaxation of the left
ventricle.
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In 2015 the International Fluid Optimization Group published a consensus
statement on perioperative fluid therapy recommendations. 26 While the document points
out that over or under hydration of perioperative patients is harmful, the most important
analysis point to the fact that as clinicians, our ability to recognize and measure fluid
sensitivity is often wrong. Previously perpetuated dogma of fluid therapy based on
“nothing by mouth” (NPO) status, preoperative state, and the patient’s weight are
unfounded and have little to no scientific evidence.26 At the same time, there is vast
variability of fluid treatment and algorithms amongst institutions and practitioners,
making research studies difficult. 27,28,29 And what we have always learned as to exist as
the “third space” has been abandoned.
Arterial compliance (change in volume over a change in pressure) decreases as
stiffness of the vasculature increases with aging. In patients with peripheral vascular
disease, this is an added detriment to the patient’s ability to adapt to changes in vascular
tone due to anesthetics. There are dynamic noninvasive measurements of “fluid
responsiveness” that can be used in cases of hemodynamic instability to assess
patient’s fluid status in the OR. These include pulse pressure variation, systolic pressure
variation, and SV variation. If greater than 20% in patients on positive pressure
ventilation, these may point to patients who are “fluid responders”. It is important to note
that these 25% of patients under general anesthesia are in what is known as the “gray”
zone”, between 8-15%. 30 As such, these indirect measurement of fluid responsiveness
may not be accurate or possible in a quarter of patients in the OR.
A fluid bolus challenge, particularly using the passive leg raise test, may be the
safest way to measure fluid responsiveness in patients that are undergoing surgery and
are hemodynamically unstable and the question whether a fluid bolus is indicated. Mini-
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boluses, such as 50-100cc, are also more recently being studied, as more and more
literature points to over hydration with previously larger boluses (500mL or more) may be
detrimental to patients who are undergoing surgery that are hemodynamically unstable.
It is important to recognize that because a patient may be a fluid responder, it
does not mean that fluid is necessary or needed. Low vascular tone, or low cardiac
contractility may need to be addressed in order to improve ventricular filling.
The recent consensus statement on perioperative fluid therapy recommended
three things be present to safely administer fluids: the need for hemodynamic
improvement, the presence of fluid responsiveness, and the lack of associated risk.
Since fluid therapy in the elderly population with LVDD has not been studied, we do not
know the associated risk of giving fluid to these patients. We know that elevated LV
pressures are associated with poor outcomes, and that diastolic dysfunction is a
precursor to diastolic heart failure, and that diastolic heart failure is treated with
decreasing afterload and improving arterial compliance and decreasing LV filling
pressures to improve coronary perfusion. We know the presence of LVDD increases
perioperative mortality, and the treatment of HFpEF involves limiting fluid therapy and
providing diuresis.1,2,3,4,5,31,32,33,34 The proposed research allowed us to begin to
understand this risk by evaluating the relationship between LV filling pressures, left
ventricular CO, and perioperative fluid management.
Primary Study Objective and Hypothesis
The primary objective of the study was to describe how moderate size fluid
boluses changed CO in elderly vascular surgery patients with LVDD. Our secondary
objective was to evaluate how moderate size fluid boluses change E/e’ in elderly patients
undergoing vascular surgery that have baseline elevated LV filling pressures (Grade II or Grade
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III LVDD) or normal filling pressures with evidence of Grade I LVDD. We performed a
prospective clinical trial to evaluate the effect of fluid boluses on intraoperative
echocardiography diastolic measurements of LVDD including CO and E/e’ in elderly
vascular surgical patients who have baseline LVDD. The clinical trial was a substudy of a
larger NIH funded grant studying the effects of an echo-guided treatment algorithm on
patients undergoing vascular surgery who had known LVDD (1R03 AG045103-01A1),
Principle Investigator: Sasha K. Shillcutt, M.D. We used an echocardiography-driven
algorithm to administer fluid boluses and measured both E/e’ and left ventricular CO
intraoperatively on TEE during vascular surgery.
Specific Aim 1
To describe how moderate size fluid boluses change CO in patients with baseline
elevated LV filling pressures (Grade II or Grade III LVDD).
Specific Aim 2
To describe how moderate size fluid boluses change E/e’ in elderly patients
undergoing vascular surgery that have baseline elevated LV filling pressures (Grade II or Grade
III LVDD) or normal filling pressures with evidence of Grade I LVDD.
We assessed changes in LVDD in the subjects by administering a series of 250 mL fluid
boluses prior to surgical incision on elderly patients undergoing vascular surgery. We then
measured changes in both filing pressures and CO in the subjects.
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CHAPTER 2: METHODS
Study Design
The study was a controlled, single-blind prospective clinical trial in patients
age 60 years or older with echocardiographic evidence of Grade I, II or III LVDD on
preoperative TTE. All study protocols were approved by the Institutional Review
Board at the University of Nebraska Medical Center.
Study Population
Study population included patients undergoing vascular surgery 60 years of age or
older at the University of Nebraska Medical Center. Screening took place in the
Preanesthesia Screening Clinic (PASC) outpatient clinic. The study population included
both male and female patients age 60 years or older who had echocardiographic
evidence of Grade I, II or III LVDD on preoperative TTE examination and met
inclusion/exclusion criteria (Table 1). The subjects were undergoing any one of the
vascular procedures listed below.
1. Open abdominal aortic aneurysm (AAA) repair
2. Endovascular aortic repair (EVAR)
3. Lower extremity bypass (LEB)
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Inclusion and Exclusion Criteria
The inclusion criteria and exclusion criteria of the study subjects are listed in Table 1
below.
Inclusion Criteria
Age 60 years and
older

Exclusion Criteria

Exclusion Justification

Patients with
expected hospital stay
< 24 hours

Inability to assess
outcome measures

Echocardiographic
Evidence of Grade I, II
or III LVDD on
Preoperative TTE
examination

Inability to
undergo TEE and
TTE

Inability to obtain
echo measurements

Clinical
evidence/suspicion of
elevated ICP

Increase risk of decreased
brain perfusion

Undergoing vascular
procedures listed
below:

Preoperative shock
or systemic sepsis

Inability to properly
consent patients

1. Lower extremity
bypass (LEB)

Emergency operation

Inability to properly
consent patients

2. Open abdominal aortic
aneurysm (AAA)
repair

American Society of
Anesthesiologists Status
V

Inability to properly
consent patients

3. Endovascular
aortic repair
(EVAR)

Participation in
another clinical trial

Interference with study findings

4. Ability to read,
understand, and sign
consent form
Table 1: Study Inclusion and Exclusion Criteria

Study Enrollment
Potential study subjects were approached during their pre-surgical visit in the
PASC by study investigators based on inclusion/exclusion criteria. Once informed
consents were obtained, eligible patients underwent a screening TTE. Further enrollment
into the study then required TTE evidence of LVDD based on echocardiography criteria
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for LVDD (see Figure 2). Subjects were then given a screening grade of LVDD (I, II or
III) as described in Figure 2. The primary Grade of LVDD was given based on e’, then
E/e’. While E/A ratio was considered as a secondary factor, LVDD Grade was assigned
based on E/e’ only.
Figure 2: Preoperative Echocardiography Criteria and Grading of LVDD

Figure 2: Preoperative Echocardiography Criteria and Grading of LVDD.
e’ = lateral mitral annular tissue Doppler velocity, E = peak early mitral inflow velocity, A =
late mitral inflow velocity, LVDD = Left ventricular diastolic dysfunction

Echocardiography Data Points
The first TTE completed was considered the screening TTE in the PASC, and
labeled as such. Immediately prior to induction of anesthesia and the day of planned
surgery, another TTE was performed to collect diastolic indices listed in Table 2 and
labeled as the baseline TTE. This baseline TTE was done the day of surgery to ensure
that any differences in diastolic indices noted on intraoperative TEE when compared

14

to the screening TTE were less likely to be influenced by NPO status.
Table 2: Echocardiography Data Points Collected during Screening TTE, Baseline
TEE and Intraoperative TEE Examination
Echocardiography

Screening TTE

Intraoperative TEE

Left Ventricular Wall

Parasternal SAX

Assessed by TTE only

Left Atrial Volume Index

Apical 4C

Unable to assess by 2D TEE

Left Ventricular
Ejection Fraction
(biplane method)

Apical 4C, 2C, LAX,
Parasternal SAX

ME 4C, 2C, LAX,
Transgastric SAX

Pulmonary Vein Flow

Apical 4C

ME 2C

E velocity, Deceleration

Apical 4C

ME 4C

e'

Lateral mitral annulus,
averaged over 3 beats,
Apical 4C

Lateral mitral annulus,
averaged over 3 beats,
ME 4C

LVOT diameter

Parasternal LAX

ME AV LAX

LVOT VTI (for Stroke
Volume)

Apical LAX

Deep gastric LAX

Table 2: Echocardiography data points and their corresponding windows/views for
both the TTE and TEE examinations performed.
AV = Aortic Valve; C = Chamber; e’ = lateral mitral annular tissue Doppler velocity,
LAX = Long Axis View; ME = Midesophageal; SAX = Short Axis View VTI =
velocity time integral, LVOT = Left ventricular Outflow Tract, E velocity = Peak
mitral early inflow velocity

Study Interventions
After the induction of anesthesia and prior to surgical incision, a TEE probe was
inserted into the subjects’ esophagus and a CX50 ultrasound machine with an S5-1
sector array transducer probe or IE33 ultrasound machine using an X7-2t matrix array
probe (Philips, Philips Healthcare, Andover, MA) was utilized for echocardiography data
collection. Intraoperative TEE data points collected are listed in Table 2. The TEE probe
was inserted per institutional research TEE protocol. Each subject was analyzed for two
main measurements: Doppler derived left ventricular end diastolic pressure (E/e’) and
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SV/CO using Doppler-derived velocity time integral (VTI) and left ventricular outflow tract
(LVOT) diameter.
The E/e’ was derived by using the E velocity obtained in the Midesophageal
4 Chamber view (ME 4C) and the e’ velocity obtained at the lateral mitral valve
annulus also in the ME 4C view. Left ventricular CO was calculated by using the
following equations: πr2 x LVOT VTI x Heart Rate = left ventricular CO where VTI =
the left ventricular VTI and r = LVOT diameter/2. Those values were entered into an
electronic data collection form as T 0 (Time zero) Intraoperative TEE.
Interventions and Duration
After initial measurements of CO and E/e’ were taken, a 250 mL bolus of
normal saline (NS) was administered to the subject via a peripheral intravenous
catheter for subjects who had normal Grade LVDD, Grade I LVDD, or Grade II
LVDD. Subjects with Grade III LVDD were not transfused the bolus of fluid due to
risk of pulmonary edema. After the first bolus was complete, repeat measurements
of CO and E/e’ were taken and documented into the electronic database. It is
important to note that while we did not have any patients on screening TEE who
had normal LVDD Grade (Grade 0), we had to include Grade 0 in the clinical
algorithm, as some subjects theoretically could have a change in LVDD Grade from
Grade I to Grade 0 during the perioperative period (as seen in a change from Grade
I on screening TTE, for example, to Grade O on the Preoperative TTE), as
evidenced by our pilot study.
A clinical fluid algorithm was then used based on the subject’s change in
CO to the initial 250 mL bolus seen in Figure 3. If after one 250 mL bolus there was
an increase in CO, a second bolus was administered. If there was no change in CO
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or if the CO decrease with fluid bolus administration then no more fluid boluses
were given.
After the second 250 mL bolus of NS repeat CO and E/e’ measurements
were assessed. If after the second 250 mL bolus there an increase in CO, a third
and final 250 mL bolus was administered and both CO and E/e’ measured and
entered in the database as per algorithm listed in Figure 3.

Figure 3: Intraoperative Fluid Bolus Algorithm

Figure 3: Algorithm for fluid bolus of 250 mL normal saline (NS) and response of cardiac
output.
CO = cardiac output, LV = left ventricle, ml = milliliters
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Data Collection
Patient demographics, comorbidities, surgical status and TTE/TEE examination
data was collected and placed into an electronic database with the corresponding time
interval in which the data was collected. Hemodynamic measurements (blood pressure,
pulse, pulse oximeter) were automatically placed into the EMR from the hemodynamic
monitor intraoperatively for any further analysis, as were all drugs administered
intraoperatively.
Clinical Endpoints
The clinical end points measured are listed below in Table 3. While the
intervention was driven on the change in left ventricular CO from fluid bolus, early (E)
and late (A) mitral inflow peak velocities, pulmonary vein flow patterns of systolic or
diastolic dominance, E/e’, and left ventricular ejection fraction were also measured as
seen in Table 3.

Table 3: Clinical Endpoints Measured
Demographic
Age
Sex
BMI
Race
Surgical Procedure
Endpoint
Left Ventricular Cardiac Output
Peak Early Mitral Inflow Velocity
Peak Late Mitral Inflow Velocity
Pulmonary Vein Flow Pattern
Left Ventricular Ejection Fraction
Lateral Mitral Annular Tissue Doppler Velocity
LVDD Grade

Measurement

Measurement
πr2 x LVOT VTI x Heart Rate
E
A
Systolic or Diastolic Dominant
EF% by biplane method
e’
0, I, II, III

Table 3
BMI = body mass index, LVDD = left ventricular diastolic dysfunction
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Data Collected Per Time Period
LVDD Grade, LV CO and E/e’ were collected at six different time periods as
listed in Figure 4:

Screening TTE

Baseline
TTE

T0 TEE

TEE
Bolus 1

TEE
Bolus 2

TEE
Bolus 3

Figure 4. Timeline of echocardiography data points.
TTE=transthoracic echocardiography, TEE=transesophageal echocardiography

•

Screening TTE (performed in PASC)

•

Baseline TTE (performed day of surgery, prior to induction)

•

T 0 TEE (performed after induction of anesthesia, prior to incision)

•

TEE Bolus 1 (performed after first 250 mL NS bolus)

•

TEE Bolus 2 (performed after first 250 mL NS bolus)

•

TEE Bolus 3 (performed after first 250 mL NS bolus)

Statistical Considerations
Descriptive statistics were used to describe patient demographics and changes
within LVDD grade. Counts, percentages were used for categorical data and means and
standard deviations for continuous data. Side by side box plots were used to show the
distribution of LVDD grade, CO, and E/e’.
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CHAPTER 3: RESULTS
Seventeen subjects were identified in the PASC that met study criteria and
enrolled in the study. One subject voluntarily withdrew from the study during the
Preoperative TTE leaving a total number of subjects enrolled=16.
Baseline Characteristics
The average subject age was 74 years. There were 12 (75%) males and 4
females (25%). Average BMI was 26 kg/m2. Table 4 lists the subject characteristics,
cardiac risk factors and comorbidities. The surgical procedure type is also listed in Table
4.

Table 4: Subject Characteristics, Comorbidities and Surgical Procedure Type
Study Subjects (N=16)
[n (%)] or [Mean (SD)]
Subject Demographics
• Male Sex
• Age (years)
• BMI (kg/m2)
• Race
Caucasian
African American

12 (75%)
74.0 (7.7)
26 (7.0)
15 (94%)
1 (6%)

Cardiac Risk/Comorbidities
•
•
•
•
•
•
•

Hypertension
Peripheral Vascular Disease
CAD
COPD
Chronic Kidney Disease
Diabetes Mellitus
Cerebral Vascular Accident

Surgical Procedure Type
• Open AAA Repair
• EVAR
• LE Bypass/Repair/Stent

13 (81%)
9 (56%)
7 (44%)
7 (44%)
7 (44%)
4 (25%)
2 (13%)

4 (25%)
5 (31%)
7 (44%)

Table 4: Subject demographics, risk factors and comorbidities and surgical procedure of
the N=16 subjects.
AAA=abdominal aortic aneurysm, BMI=body mass index, CAD=coronary artery disease
COPD=chronic obstructive pulmonary disease, EVAR=endovascular aortic repair,
LE=lower extremity, SD=standard deviation
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Preoperative Screening TTE Examination
The Preoperative Screening TTE data collected and Grade of LVDD is listed in
Table 5. All subjects were found to have evidence of LVDD (Grade I, II) on screening
TTE examination. Ten (63%) subjects had Grade I, while six subjects had Grade II
(37%). None of the subjects had evidence of LVDD Grade III on screening TTE.

Table 5: Preoperative Screening TTE Data, N=16
Screening TTE Data
Left Ventricular Ejection Fraction (%)
Left Ventricular Cardiac Output (L/min)
e’
E/e’
Preoperative Screening Grade of LVDD
• LVDD Grade I
• LVDD Grade II
• LVDD Grade III

N=16 [n (%)] or [Mean (SD)]
51 (8.04)
5.2 (1.7)
8.3 (2.7)
10.2 (3.1)
10 (63%)
6 (37%)
-

Table 5: Preoperative screening data from the PASC screening TTE examination.
TTE=transthoracic echocardiogram, E= peak early mitral inflow velocity. e’=lateral mitral
annular tissue Doppler velocity, L/min=liters/minute, LVDD=left ventricular diastolic
dysfunction

Day of Surgery Baseline TTE Examination
The Preoperative Baseline TTE data collected and Grade of LVDD is listed in
Table 6. Fifteen of the 16 subjects were found to have LVDD Grade I [N=12 (75%)] or
Grade II [N=3 (19%)] on the preoperative baseline TTE examination the day of surgery.
On one of the subjects changed to LVDD Grade I from Grade II on the screening TTE
while one subject when from Grade I to normal left ventricular diastolic function the day
of surgery when compared to the screening PASC TTE.
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Table 6: Preoperative Day of Surgery Baseline TTE Data (N=16)
Baseline TTE Data
Left Ventricular Ejection Fraction (%)
Left Ventricular Cardiac Output (L/min)
e’
E/e’
Preoperative Screening Grade of LVDD
• LVDD Normal (Grade 0)
• LVDD Grade I
• LVDD Grade II
• LVDD Grade III

N=16 [n (%)] or [Mean (SD)]
52.5 (5.2)
5.1 (2.2)
8.5 (2.3)
9.9 (3.3)
1 (6%)
12 (75%)
3 (19%)
-

Table 6: Preoperative Baseline data from the Day of Surgery baseline TTE examination.
TTE=transthoracic echocardiogram, E= Peak Early Mitral Inflow Velocity. e’=Lateral Mitral
Annular Tissue Doppler Velocity, L/min=liters/minute, LVDD=left ventricular diastolic
dysfunction

Anesthetic Data
All subjects underwent general anesthesia technique with intravenous induction
and maintenance of anesthesia with vapors and narcotics. Saline intravenous flushes in
10 mL syringes were used to push anesthetic drugs for induction to minimize “free-flow”
fluid administration. Drugs utilized in study subjects for induction and anesthetic
maintenance are listed in Table 7.
Intraoperative TEE Examination (T 0 )
Table 7: Anesthetic Drugs Utilized in Study (N=16)

Anesthetic Drug Utilized
propofol
fentanyl
midazolam
cisatricurium
sevoflorane
desflurane
sufentanil
rocuronium

N=16
16 (100%)
15 (94%)
13 (81%)
13 (81%)
12 (75%)
4 (25%)
4 (25%)
3 (19%)

Table 7: Induction and maintenance anesthetic drugs utilized for the study population.
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The Intraoperative TEE data collected performed at T0 (after induction of
anesthesia and prior to fluid intervention administration) is listed in Table 8. On initial
intraoperative TEE (T 0 ) 10 subjects had Grade I, four subjects had Grade II, and two
subjects had changed to LVDD Grade 0, or had normal appearing diastolic function. No
subjects at T 0 had LVDD Grade III.

Table 8: Intraoperative TEE Data T0 (N=16)
Intraoperative TEE Data

Left Ventricular Ejection Fraction (%)
Left Ventricular Cardiac Output (L/min)
e’
E/e’
Preoperative Screening Grade of LVDD
• LVDD Grade 0 (Normal)
• LVDD Grade I
• LVDD Grade II
• LVDD Grade III

TEE T0
N=16
53 (7.2)
4.9 (2.0)
8.8 (2.6)
8.7 (4.5)
2
10
4
-

TEE
Bolus 1
N=16
4.6 (1.6)
9.4 (3.1)
8.2 (3.9)
1
9
6

TEE
Bolus 2
N=7
4.6 (1.5)
8.9 (2.5)
7.8 (2.3)

TEE
Bolus 3
N=2
5.0 (0.5)
8.0 (2.8)
8.5 (2.4)

4
2
1

2
-

Table 8: Intraoperative TEE Data T0 collected after induction of anesthesia and prior to
fluid bolus intervention. After each 250mL bolus of NS, cardiac output and E/e’ were
calculated and their values recorded per clinical algorithm listed in Figure 3.
TTE=transthoracic echocardiogram, E= Peak Early Mitral Inflow Velocity. e’=Lateral Mitral
Annular Tissue Doppler Velocity, L/min=liters/minute, LVDD=left ventricular diastolic
dysfunction

Primary Outcome Data
For the entire subject cohort (N=16), the overall CO decreased after Bolus 1 (250
mL) from 4.9 L/min to 4.6 L/min. Nine subjects (9/16, 56%) had no change or a decrease
in CO with Bolus 1. Seven subjects (7/16, 44%) had an increase in CO with Bolus 1 and
underwent Bolus 2 (250 mL). After Bolus 2, two subjects (N=2/7, 29%) had an increase
in CO. A side-by-side boxplot showing the distribution of CO at each of the six time
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periods (Screening TTE, Baseline TTE, T 0 TEE, TEE Bolus 1, TEE Bolus 2, and TEE
Bolus 3) is noted below in Figure 5.

Figure 5: Left Ventricular Cardiac Output Distribution at Each Time Period

Figure 5: Box Plot depicting the distribution of LV CO at each time period. All subjects (N=16)
received the 1st bolus of 250 mL of NS, and then had TEE Bolus 1 data collected. Seven subjects
received a 2nd bolus of 250 mL, while only 2 subjects had the 3rd bolus and TEE data collected.
N=subject number, TEE= transesophageal echocardiography, TTE=transthoracic
echocardiography, T0=time zero

Individual patient plots of CO, over each time period, are listed in Figure 6.
Trends at each time period are shown.

24

Figure 6. Individual Patients CO per Time Period

Cardiac Output (mL) Per Patient by Time Period
12000.00

Cardiac Output (mL)

10000.00

8000.00
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0.00
Screening TTE

Baseline TTE

To TEE

TEE Bolus 1

TEE Bolus 2

TEE Bolus 3

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

Patient 11

Patient 12

Patient 13

Patient 14

Patient 15

Patient 16

Figure 6: Individual patient’s Cardiac Output at each time period.
CO=cardiac output, mL = milliliters, TEE= transesophageal echocardiography, TTE=transthoracic
echocardiography, T0=time zero
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Secondary Outcome Data
A side-by-side boxplots showing the distribution of E/e’ at each of the six time
periods (Screening TTE, Baseline TTE, T 0 TEE, TEE Bolus 1, TEE Bolus 2, and TEE
Bolus 3) is listed below in Figure 7. The E/e’ decreased from 8.7 to 8.2, while e’
increased from 8.8 to 9.5.

Figure 7: Left Ventricular E/e’ Distribution at Each Time Period

Figure 7: Box Plot depicting the distribution of E/e’ at each time period. All subjects
(N=16) received the 1st bolus of 250 mL of NS, and then had TEE Bolus 1 data collected.
Seven subjects received a 2nd bolus of 250 mL, while only 2 subjects had the 3rd bolus
and TEE data collected.
N=subject number, TEE= transesophageal echocardiography, TTE=transthoracic
echocardiography, T0=time zero
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Figure 8 displays Individual patient plots of E/e’ over each time period. Trends at each
time period are shown.
Figure 8: Individual Patient E/e’ per Time Period

E/e' Per Patient by Time Period
20.00
18.00
16.00
14.00

E/e-

12.00
10.00
8.00
6.00
4.00
2.00
0.00
Screening TTE

Baseline TTE

T0 TTE

Bolus 1

Bolus 2

Bolus 3

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

Patient 7

Patient 8

Patient 9

Patient 10

Patient 11

Patient 12

Patient 13

Patient 14

Patient 15

Patient 16

Figure 8: Individual patient’s E/e’ at each time period.
TEE= transesophageal echocardiography, TTE=transthoracic echocardiography, T0=time zero
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Changes in LVDD Grade
The frequency distribution of LVDD Grade at the six time periods (Screening
TTE, Baseline TTE, T 0 TEE, TEE Bolus 1, TEE Bolus 2, and TEE Bolus 3) is displayed
below in a clustered bar chart in Figure 9. Five (N=5/16, 31%) subjects had a changes in
LVDD Grade after the first bolus.

Figure 9: Left Ventricle Diastolic Dysfunction Grade Distribution at Each Time
Period

Figure 9: Box Plot depicting the distribution of LVDD Grade at each time period. All
subjects (N=16) received the 1st bolus of 250 mL of NS, and then had TEE Bolus 1 data
collected. Seven subjects received a 2nd bolus of 250 mL, while only 2 subjects had the
3rd bolus and TEE data collected.
N=subject number, TEE= transesophageal echocardiography, TTE=transthoracic
echocardiography, T0=time zero
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Seven subjects had an improvement in CO after the first bolus, and hence then
received a second bolus per protocol. The seven subjects who had an improvement in
CO, the majority of them (N=5/7,97%) were LVDD Grade I. Two of the subjects were
Grade II.
Of those seven subjects, two (N=2/7, 29%) had a change in LVDD Grade after
the second bolus. Both of the subjects had an increase in LVDD (one subjects changed
from LVDD Grade I to II, while the other went from Grade II to Grade III. Two subjects
had an improvement in CO, and received a third bolus of 250 mL NS. One of the two of
subjects (N=1/2) changed his/her LVDD Grade from Grade II to Grade I.
Safety Data
There were no adverse events reported with TEE probe insertion or removal or
the performance of the TEE. There were no incidences of difficult probe placement or
withdrawal. The subjects’ medical record was reviewed at hospital discharge and there
were no reported oropharyngeal, esophageal or gastric trauma related to the TEE.
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CHAPTER 4: DISCUSSION
The primary aim of this study was to evaluate the effect of fluid administration on
left ventricular CO in surgical patients with evidence of LVDD. LVDD is risk factor for
diastolic heart failure, and perioperative risk is increased for events such CHF and
myocardial infarction in patients that have often asymptomatic LVDD.7 The direct effects
of fluid administration during vascular surgery have not been studied in this population.
This study found that in the majority of 16 vascular surgical subjects with LVDD, the
administration of fluid boluses did not increase left ventricular CO.
While the administration of fluids is contraindicated in patients that have clinical
heart failure, and preclinical evidence of LVDD is a risk for heart failure, perioperatively
fluid administration to surgical patients is often warranted due to surgical blood loss,
shifts in fluid, and insensible losses. Guidelines and expert recommendations on how to
approach fluid administration during the perioperative period for patients that have LVDD
are lacking. As such, this study sought to evaluate the effects of fluid in patients with
LVDD undergoing vascular surgery with real-time hemodynamic indices such as Doppler
derived CO and also left ventricular end-diastolic pressure derived from Doppler
echocardiography.
We saw that in 16 elderly surgical subjects with LVDD, there was a trend that
250 mL fluid boluses did not increase CO in nine of 16 of patients. In patients who did
have a rise in CO with the fluid bolus, they were more likely to have LVDD Grade I and
normal Doppler-derived left-sided filling pressures. This would support idea that in
patients with LVDD Grade I, LV filling pressures are likely normal, and the risk of
developing CHF or diastolic heart failure may be lower than in patients with higher grade
of LVDD and higher left-sided filling pressures. As such, a more liberal approach to
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administration of perioperative fluids may be less likely to cause postoperative adverse
events such as heart failure. Preoperative screening of patients and classification of
LVDD Grade may provide information to guide anesthesiologists on perioperative fluid
administration decisions. In the perioperative arena, where fluid boluses are often
required and necessary, some patients with LVDD Grade I may respond to fluid
challenges with an improvement in LV CO as suggested by this pilot data. Whereas
patients that have advanced stages of LVDD, such as LVDD Grade II or III, may not see
this benefit. As such, the risk/benefit analysis of fluid administration to this population
needs to be analyzed with future outcome studies.
The second aim of the study was to evaluate if and how fluid boluses changed
E/e’, or Doppler-derived filing pressures, in subjects with LVDD Grade II and Grade III.
We saw a trend that moderate fluid boluses did not change E/e’, they may change LVDD
Grades. For example, after the first 250mL bolus, we found 4 subjects (N=4/16, 25%)
demonstrated an increase in their LVDD Grade, suggesting an increase in LV filling
pressures. This was also demonstrated in two subjects (N=2/7, 29%) who qualified for a
second fluid bolus of 250mL. While 5 subjects demonstrated no change in LVDD Grade,
two subjects demonstrated a worsening LVDD Grade. While this section of the study
was not powered to evaluate clinical outcomes, previous studies have demonstrated that
patients with worsening LVDD Grade have worse clinical outcomes.4,7,8 A further study
evaluating the change in subjects LVDD grade that is powered to demonstrate a
correlation with an increase in adverse outcomes is currently underway.
This second aim provides more insight into the direct effects of fluid
administration to two often coupled indices: E/e’, or Doppler-derived LV filling pressure
(LVEDP), and LVDD Grade. While we know these two measurements are directly
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proportional, whereas and increase in E/e’ theoretically leads to an increase in LVDD
Grade, there seems to be more to this relationship than a pure linear association. As
E/e’ is a continuous variable versus LVDD Grade being categorical (0, I, II, III), it can be
extrapolated that there will be changes in LVDD Grade, which has been historically
derived from mitral inflow velocity patterns and pulmonary vein flow velocity patterns
which may or may not be reflected in E/e’, which is derived from both mitral inflow
velocity and tissue-Doppler velocity. The fact that fluid boluses were found to result in a
worsening of LVDD Grade in some subjects but did not result in a significant change in
E/e’ suggests that these indices may reflect different physiological changes. The
differences in response to fluid boluses between these two indices may be better
explained by the effect of the loading conditions, whereas mitral inflow velocities and
pulmonary vein flow velocities are more load-dependent, where e’ is well understood to
be less dependent on loading conditions.5,16 Which of these indices do in fact change
more with fluid administration, and whether those changes are tied to differences in
clinical outcomes, is part of the adjunct clinical trial underway.
The findings in this study, similar to our preliminary study, demonstrate the
dynamic and sensitive nature of LVDD Grade.25 The Grade of LVDD, which has been
traditionally determined by mitral inflow patterns and pulmonary vein flow patterns and
tissue Doppler velocity of the mitral annulus, can change with loading conditions during
the perioperative period, as shown in our pilot study and repeated in this study. The fact
that LVDD Grade can change with fluid administration begs one to wonder if
anesthesiologists who administer perioperative fluids to high-risk patients can optimize
fluid administration, resulting in optimizing LVDD Grade and LV CO. And if
anesthesiologists can optimization fluids based on a patient’s baseline LVDD Grade,
does this lead to an optimization of postoperative outcomes?
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Vascular surgical patients, most of which are elderly, present a special set of
challenges to the anesthesiologist. Risk factors such as hypertension, advanced age,
coronary artery disease (CAD), and renal dysfunction are common in the vascular
surgical population. Arterial hypertension and higher baseline perfusion pressures, along
with reperfusion injury associated with the cross-clamping and release of major
vasculature during surgery make it very challenging for the anesthesiologist to maintain
adequate organ perfusion and avoid post-operative organ failure. 35 Optimizing fluid
management is very important to perioperative organ perfusion. 36 The disruption of the
capillary barrier, from either hypovolemia or hypervolemia, is associated with poor
outcomes, leading to current investigations to suggest GDT may lead to improved
postoperative outcomes in major surgery.36,37
GDT, targeted at providing euvolemia and avoidance of excess salt and water,
plays an important part of improving outcomes in major surgery and in high risk patients,
who often have a hard time excreting water and/or salt due to comorbidities. But what is
GDT in patients with LVDD? This study adds to the first step in defining GDT in this
population.
The previous mantra of “filling the third space” has been disbanded as this space
does not exist physiologically.35, 36,37, 38 However, for the last century, the doctrine of filling
the third space, a “hidden” area within the body thought to consume volume in
perioperative patients, has been perpetuated from generation to generation of
physicians. Despite our recent knowledge that this space does not exist, trends in fluid
administration illustrate that many clinicians still practice liberal fluid practices based on
this theory, institutional preferences, and surgical tendencies.27 Intraoperative insensible
losses, once thought to require maintenance fluid replacement as high as 10-20
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mg/kg/hour, are now known to be much lower, and 0.5-1 mg/kg/hour is the accepted
replacement therapy to avoid capillary leak and interstitial edema.35,36,37 In order to
optimize fluid management, GDT has recently been adopted, where fluid administration
is based on physiological needs and hemodynamic data such as SV. While GDT has
been shown to be beneficial in many surgical arenas, it is not practiced in most
institutions. The institution of GDT into perioperative practice has been limited due
requirements of a focused evaluation of hemodynamic measurements such as SV or
CO, which many institutions lack the resources to fulfill. Current studies in major
abdominal surgery have shown that fluid protocols and algorithms supporting GDT are
associated with improved outcomes.36,39 Recent meta-analyses and reviews suggest it is
not the type or amount of fluid that is most important, but rather following a protocol
based on hemodynamic data.39
SV is considered to be the gold standard for measuring a patient’s response to
fluid and where the patient is on the Frank-Starling curve.30,36, 40 Once a patient is
euvolemic, administration of fluid will result in a <10% change in SV and assumed to be
on the plateau of the Frank-Starling curve.41 While GDT using SV is invaluable, it
requires training and expertise not available to all patients. While not every patient
undergoing vascular surgery may have GDT using SV, the establishment of guidelines
and recommendations to optimize fluid management for this population may be
beneficial to shift the current paradigms. As this study revealed, changes in LVEDP and
SV/CO with fluid boluses may not be as predictable in the patients with LVDD. Vascular
surgery, unlike major abdominal surgery, has its own set of challenges for euvolemia
that may make GDT even more helpful in this population and higher risk surgical
procedure.

34

Can perioperative fluid algorithms optimize hemodynamics and outcomes in
patients with LVDD undergoing vascular surgery? The answer to this question has not
been studied. While general preventative practices to avoid diastolic heart failure in
patients with LVDD exist, we do not know how to avoid diastolic heart failure in surgical
patients with LVDD, many of which undergo vascular surgery. This study is the first
study to measure SV and CO response to fluid boluses in high-risk patient undergoing
vascular surgery. While heart rate and mean arterial pressure are the traditional
mainstay of clinicians to determine response to fluid, they are poor estimates of true
circulating blood volume and hypovolemia. A meta-analysis by Marik and colleagues
found that only 50% of patients who are hemodynamically unstable are fluid
responders. 41 In vascular surgical patients, fluid optimization is critical. Clamping and
unclamping of the aorta and major vessels, reperfusion of organs, potential for
hemorrhage, and protection of organs require significant fluid management during the
surgical period. High risk patients with vascular disease and cardiac comorbidities
require a focused approach to fluid optimization during vascular surgery, where diseases
such as LVDD can complicate fluid requirements. Understanding the patient’s
physiological response to fluids and the risk associated with under or over hydration is
arguably one of the most difficult yet important tasks to the anesthesiologist.
Understanding how left ventricular filling pressure and SV change in response to over
and under hydration is the first step to defining this important task.
Future studies are warranted to assess the need for GDT, how GDT is defined,
and how and if GDT changes outcomes in vascular surgical patients. Anesthesiologists
are the gatekeepers of perioperative fluid management. Dissemination of target goals
and the definition of GDT to promote enhanced recovery after vascular surgery are
needed to improve anesthetic care of the elderly population who have LVDD.
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ADULT CONSENT - CLINICAL BIOMEDICAL
Title of this Research Study
Echocardiography-Guided Hemodynamic Management Strategy to Improve
Clinical Outcomes for Elderly Patients with Left Ventricular Diastolic Dysfunction
Undergoing Noncardiac Surgery

Invitation
You are invited to take part in this research study. You have a copy of the
following, which is meant to help you decide whether or not to take part:
•
•
•

Informed consent form
"What Do I need to Know Before Being in a Research Study?"
The Rights of Research Subjects

Why are you being asked to be in this research study?
You are being asked to be in this research study because you are scheduled
to undergo a major non-heart surgery at the University of Nebraska Medical Center,
and you are 60 years of age or older.

A total of 200 patients will be enrolled in the study.

What is the reason for doing this research study?
The purpose of this research is to see if echocardiography (a sound wave picture
of the heart) during surgery can help the doctor who gives the sedation
medication (Anesthesiologist) better manage fluid levels and medications during the
surgery, and reduce the chance of complications during and after the surgery

What will be done during this research study?
You will be randomly assigned (like the flip of a coin) to one of two groups
before your surgery. An equal number of patients will be assigned to each
research group. Subjects who do not have stiffening of the large chamber located
on the left side of the heart (Left Ventricular Dysfunction) also known as LVDD,
seen on echocardiogram completed prior to surgery, will be withdrawn from the
study.

All subjects will have an echocardiogram before surgery. This involves placing
a probe on your chest and taking sound wave pictures of your heart through

your chest. After you are asleep for the surgery, you will have a different
echocardiogram probe placed through your mouth into your esophagus, by the
anesthesia doctor. This will take sound wave pictures of your heart during the
entire operation. The probe will be removed before you wake up.

If you are in the EXPERIMENTAL group,the anesthesia doctor will adjust how
he gives you IV fluids, or blood pressure medicines, based on the measurements
from the pictures of your heart from the echocardiogram.

If you are in the STANDARD group, you will be treated as if you weren't in
the research. The IV fluids or blood pressure medicines you get during the
operation will be based on the anesthesia doctor's judgment, based on your
heart rate, blood pressure and physical examination.
All subjects will have data collected including: clinical outcomes (heart failure,
atrial fibrillation, arrhythmia, or other cardiac complications), blood draws, length
of stay (hospital or Intensive Care Unit), readmission to the Hospital for a
cardiac event (heart attack, A-fib, congestive heart failure, or death) at 30 or 90
days, new diagnosis of Acute Kidney Injury. All data will be collected from your
medical record; however, if no records are available, you may receive a phone call to
ensure that you have not been treated at a hospital other than UNMC. If you are
treated within 30 days of your surgery, outside of UNMC, the study team will have
your permission to collect those medical records

What are the possible risks of being in this research study?
The risks associated with the Echocardiography Guided Hemodynamic
Mangement (EGHEM) study can be related to direct injury or trauma from the
probe that goes down your throat to look at your heart (transesophageal
echocardiography (TEE)) probe, or from mismanagement of fluid and/or drug
administration during surgery. The risks from direct TEE probe trauma include
damage or tears to the throat, water being pushed in to the lungs and dental
trauma. The risks from mismanagement of fluid and/or drug administration include
acute heart attacks, abnormal fluid build-up in the lungs, kidney failure, orthostatic
hypotension (low blood pressure when changing position)and/or death.

It is possible that other rare side effects could occur which are not described in
this consent form. It is also possible that you could have a side effect that
has not occurred before.

What are the possible benefits to you?
You may benefit if you are randomized to the experimental group, and the
experimental group is found to be better than the standard group, which may
reduce your post-operative complications association with your heart. However, you
may not get any benefit from being in this research study.

What are the possible benefits to other people?
Possible benefits to society are an advancement in medical knowledge in the
management of future patients with heart disease during major surgery.

What are the alternatives to being in this research study?
Instead of being in this research study, you can choose not to participate.

What will being in this research study cost you?
There is no cost to you to be in this research study.

Will you be paid for being in this research study?
You will not be paid to be in this research study.

Who is paying for this research?
This research is being paid for by grant funds from the National Institute of
Health (NIH) and the American Society of Geriatrics. UNMC/TNMC receives money
from the NIH to conduct this study.

What should you do if you are injured or have a medical problem during this
research study?
Your welfare is the main concern of every member of the research team. If you
are injured or have a medical problem as a direct result of being in this study, you
should immediately contact one of the people listed at the end of this consent form.
Emergency medical treatment for this injury or problem will be available at the
Nebraska Medical Center. If there is not sufficient time, you should seek care from
a local health care provider.

UNMC/TNMC has no plans to pay for any required treatment or provide other
compensation. If you have insurance, your insurance company may or may not
pay the costs of medical treatment. If you do not have insurance, or if your
insurance company refuses to pay, you will be expected to pay for the medical
treatment.

Agreeing to this does not mean you have given up any of your legal rights.

How will information about you be protected?

You have rights regarding the protection and privacy of your medical
information collected before and during this research. This medical information is
called "protected health information" (PHI). PHI used in this study may include your
medical record number, address, birth date, medical history, the results of
physical exams, blood tests, x-rays as well as the results of other diagnostic
medical or research procedures. Only the minimum amount of PHI will be collected
for this research. Your
research and medical records will be maintained in a secure manner.

Who will have access to information about you?
By signing this consent form, you are allowing the research team to have access
to your PHI. The research team includes the investigators listed on this consent
form and other personnel involved in this specific study at the Institution.

Your PHI will be used only for the purpose(s) described in the section What is
the reason for doing this research study?

You are also allowing the research team to share your PHI, as necessary, with
other people or groups listed below:
The UNMC Institutional Review Board (IRB) Institutional officials designated by the
UNMC IRB
Federal law requires that your information may be shared with these groups: The
HHS Office for Human Research Protections (OHRP)
National Institutes of Health (NIH)
You are authorizing us to use and disclose your PHI for as long as the
research study is being conducted.

You may cancel your authorization for further collection of PHI for use in this
research at any time by contacting the principal investigator in writing. However,
the PHI which is included in the research data obtained to date may still be used. If
you cancel this authorization, you will no longer be able to participate in this
research.

How will results of the research be made available to you during and after the
study is finished?
In most cases, the results of the research can be made available to you when
the study is completed, and all the results are analyzed by the investigator or the
sponsor of the research. The information from this study may be published in
scientific journals or presented at scientific meetings, but your identity will be
kept strictly confidential.

If you want the results of the study, contact the Principal Investigator at the
phone number given at the end of this form or by writing to the Principal
Investigator at the following address:
Sasha K Shillcutt, MD

University of Nebraska Medical Center
981145 Nebraska Medical Center Omaha, NE 68198-1145

A description of this clinical trial will be available on www.ClinicalTrials.gov, as
required by U.S. law. This website will not include information that can identify you.
At most, the website will include a summary of the results. You can search this
website at any time.

What will happen if you decide not to be in this research study?
You can decide not to be in this research study. Deciding not to be in this
research will not affect your medical care or your relationship with the investigator
or UNMC/TNMC. Your doctor will still take care of you and you will not lose any
benefits to which you are entitled.

What will happen if you decide to stop participating once you start?
You can stop participating in this research (withdraw) at any time by contacting
the Principal Investigator or the Lead Coordinator by phone, or you may also contact
one of these individuals in writing at the following address:

Sasha K Shillcutt, MD

University of Nebraska Medical Center 981145 Nebraska Medical Center Omaha, NE
68198-1145
Deciding to withdraw will otherwise not affect your care or your relationship with
the investigator or UNMC/TNMC. You will not lose any benefits to which you are
entitled.

For your safety, please talk to the research team before you stop taking any
study drugs or stop other related procedures. They will advise you how to withdraw
safely. If you withdraw you may be asked to undergo some additional tests. You
do NOT have to agree to do these tests.

Any research data obtained to date may still be used in the research.

Will you be given any important information during the study?
You will be informed promptly if the research team gets any new information
during this research study that may affect whether you would want to continue
being in the study.

What should you do if you have any questions about the study?
You have been given a copy of "What Do I Need to Know Before Being in a
Research Study?" If you have any questions at any time about this study, you
should contact the Principal Investigator or any of the study personnel listed on this
consent form or any other documents that you have been given.

What are your rights as a research participant?
You have rights as a research subject. These rights have been explained in
this consent form and in The Rights of Research Subjects that you have been
given. If you have any questions concerning your rights or complaints about the
research, you can contact any of the following:
The investigator or other study personnel Institutional Review Board (IRB)
Telephone: (402) 559-6463 Email: IRBORA@unmc.edu
Mail: UNMC Institutional Review Board, 987830 Nebraska Medical Center, Omaha,
NE 68198-7830
Research Subject Advocate Telephone: (402) 559-6941 Email: unmcrsa@unmc.edu

Documentation of informed consent
You are freely making a decision whether to be in this research study. Signing
this form means that:
You have read and understood this consent form. You have had the consent form
explained to you.
You have been given a copy of The Rights of Research Subjects You have had your
questions answered.
You have decided to be in the research study.
If you have any questions during the study, you have been directed to talk to one of
the investigators listed below on this consent form.
You will be given a signed and dated copy of this consent form to keep.

Signature of Subject

Date

My signature certifies that all the elements of informed consent described on
this consent form have been explained fully to the subject. In my judgment, the
subject possesses the legal capacity to give informed consent to participate in this
research and is voluntarily and knowingly giving informed consent to participate.

Signature of Person obtaining consent
Date

Authorized Study Personnel Principal
Shillcutt, Sasha phone: 402-559-3685
alt #: 402-888-0164
degree: MD
Secondary
Brakke, Tara
phone: 402559-4081
alt #: 402-8882647
degree: MD

Porter, Thomas
phone: 402559-8150
degree: MD

Participating
Personnel
Chacon, Martha
(Megan) phone: 402559-4081
degree: MD

Duhachek-Stapelman, Amy phone: 402-559-4081
alt #: 402-888-1126
degree: MD

Schulte, Thomas phone: 402-559-4081
alt #: 402-888-2366
degree: MD

Goergen, Katie phone: 402-559-4081
alt #: 402-559-4081
degree: MD

Lisco, Steven
phone: 402559-5780
alt #: 402-5595780
degree: MD

Markin, Nicholas (Nick) phone: 402-559-3814
alt #: 402-321-4018
degree: MD

Ringenberg,
Kyle phone:
402-559-4081

Roberts, Ellen phone: 402-559-4081
degree: MD

